PVCT Provectus Biopharmaceuticals Inc

All PVCT filings Filing statistics SEC Website

Provectus Biopharmaceuticals Inc. (Provectus or the Company), a Delaware corporation formed in 2002, is a clinical-stage biotechnology company developing a new class of drugs based on halogenated xanthenes, which are chemical small molecules, such as Rose Bengal, which has a molecular formula of 4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodofluorescein. Intratumoral (IT) (aka intralesional or IL) injection of PV-10, the first small molecule oncolytic immunotherapy, can yield immunogenic cell death and stimulate tumor-specific reactivity in circulating T cells. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal (GI) cancers, and preclinical study for pediatric cancers. Topical application of PH-10, an investigational formulation of Rose Bengal for dermatology, can modulate inflammation. PH-10 is undergoing clinical study for inflammatory dermatoses, like psoriasis and atopic dermatitis. Pathways significantly improved by PH-10 include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons.

Company profile

Ticker

PVCT

Exchange

NASDAQ

CEO

Bruce Horowitz

Incorporated in

Delaware

Location

Tennessee

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Warner Chilcott • Teva Pharmaceutical Industries • Abbott Laboratories • Bristol Myers Squibb • AbbVie • Mylan • Celgene ...

Former names

Provectus Pharmaceutical Inc, Provectus Pharmaceuticals Inc, SPM Group Inc, Zamage Digital Imaging Inc

SEC CIK

0000315545

Corporate docs

Articles of Incorporation & Bylaws

Subsidiary Companies

IRS number

900031917

PVCT stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart PVCT financial data

Download latest Excel data (2019 Q2) View latest Excel data (2019 Q2)

Quarter (USD)	Jun 19	Mar 19	Dec 18	Sep 18
Revenue
Net income	-2.18M	-1.37M	-2.19M	-1.61M
Diluted EPS	-0.01	0	0	0
Operating income	-1.84M	-1.8M	-1.9M	-1.36M
Net change in cash	-443.67K	1.72M	-180.93K	101.29K
Cash on hand	1.32M	1.77M	50.99K	231.92K

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue				0
Net income	-8.15M	-13.52M	-24.43M	-24.5M
Diluted EPS	-0.02	-0.04	-0.12	-0.13
Operating income	-8.05M	-13.32M	-24.51M	-24.65M
Net change in cash	-54.52K	-1.06M	-13.01M	-3.21M
Cash on hand	50.99K	105.5K	1.17M	14.18M

Financial data from company earnings reports

Financial report summary

Competition

ICH

Management Discussion

Research and development costs totaling $4,747,557 for 2018 included payroll of $521,969, consulting and contract labor of $3,053,753, lab supplies and pharmaceutical preparations of $83,134, conferences of $20,976, insurance of $285,853, rent and utilities of $65,989, depreciation and amortization expense of $679,767, and miscellaneous expenses of $36,116.
Research and development costs totaling $8,203,926 for 2017 included payroll of $509,615, consulting and contract labor of $6,407,863, conferences of $84,960, lab supplies and pharmaceutical preparations of $147,272, insurance of $310,432, rent and utilities of $56,799, and depreciation and amortization expense of $686,985.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abovementioned, achieve, acidic, activation, activity, Acute, administered, aka, allocated, autophagy, baseline, behalf, biological, blood, blue, breast, bright, burden, cancer, carcinoma, care, central, characterizing, checkpoint, Christian, CI, closure, collateral, colorectal, component, consented, contrast, costly, Dale, de, degradation, deliver, demonstrate, die, disclaimed, disodium, display, distinct, Don, duration, Duve, environment, Ewing, exposure, expression, factor, family, FDA, Food, formulation, GI, Glenn, goal, hematology, hepatocellular, high, higher, highly, human, ideal, identical, immune, imputed, inflamed, inflammasome, inhibitor, injectable, injection, input, insoluble, intracellular, intratumoral, lactone, led, lesional, leukemia, linked, low, Lumenal, lung, lysosomal, manufacturing, mechanism, membrane, mL, model, monotherapy, murine, mutation, negotiated, negotiating, neuroblastoma, neuroendocrine, Nobel, ocular, opportunity, option, Orphan, osteosarcoma, personnel, physicochemical, plasmalemma, play, Pledge, POC, prepayment, Prize, pro, product, protected, quicken, randomized, rapid, rata, red, regulatory, removed, Repayment, represent, resistant, restricted, rhabdomyosarcoma, role, rupture, safety, saline, salt, sarcoma, selectively, showed, shown, skin, SOC, soluble, solution, specifically, staining, strategy, suicide, supplied, Systemic, table, tissue, trap, treated, treatment, trial, trypan, unknown, unmet, utilize, uveal, valuation, vested, vesting, Viral, volatility

Removed: amortization, applicability, auditing, automatically, breach, Carolina, Circuit, clinically, complementary, comply, conference, contract, depreciation, duty, earlier, equal, fiduciary, important, intentional, iv, Knox, lab, Mecklenburg, misrepresentation, negligence, negligent, North, patent, patient, pharmaceutical, primarily, program, radiotherapy, rational, single, stage, targeted, therapeutic, transition, travel, widely

From filing 10-Q 2019 Q2